• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.07% Nasdaq Up0.32%

    Clovis Oncology, Inc. (CLVS)

    80.54 Up 4.46(5.86%) 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Clovis Oncology, Inc.
    2525 28th Street
    Suite 100
    Boulder, CO 80301
    United States - Map
    Phone: 303-625-5000
    Fax: 303-245-0360
    Website: http://www.clovisoncology.com

    Index Membership:N/A
    Full Time Employees:136

    Business Summary 

    Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates which include Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements with Advenchen Laboratories LLC, Avila Therapeutics, Inc., and Pfizer Inc.; collaboration and license agreement with Les Laboratoires Servier; a drug discovery collaboration agreement with Array BioPharma Inc.; collaboration with Foundation Medicine, Inc.; and clinical trial collaboration with Genentech for lung cancer treatment. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Clovis Oncology, Inc.

    Corporate Governance 
    Clovis Oncology, Inc.’s ISS Governance QuickScore as of Aug 1, 2015 is 8. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Patrick J. Mahaffy MA, 52
    Co-Founder, Chief Exec. Officer, Pres and Director
    Mr. Erle T. Mast , 53
    Co-Founder, Chief Financial Officer, Exec. VP and Sec.
    Dr. Gillian C. Ivers-Read BSc, 61
    Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations
    Mr. Steven L. Hoerter , 44
    Chief Commercial Officer and Exec. VP
    Ms. Breanna Burkart ,
    Sr. Director of Investor Relations
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders